Obesity in South and Southeast Asia-A new consensus on care and management
- PMID: 36453081
- PMCID: PMC10078503
- DOI: 10.1111/obr.13520
Obesity in South and Southeast Asia-A new consensus on care and management
Abstract
Obesity is a chronic disease in which the abnormal or excessive accumulation of body fat leads to impaired health and increased risk of mortality and chronic health complications. Prevalence of obesity is rising rapidly in South and Southeast Asia, with potentially serious consequences for local economies, healthcare systems, and quality of life. Our group of obesity specialists from Bangladesh, Brunei Darussalam, India, Indonesia, Malaysia, Philippines, Singapore, Sri Lanka, Thailand, and Viet Nam undertook to develop consensus recommendations for management and care of adults and children with obesity in South and Southeast Asia. To this end, we identified and researched 12 clinical questions related to obesity. These questions address the optimal approaches for identifying and staging obesity, treatment (lifestyle, behavioral, pharmacologic, and surgical options) and maintenance of reduced weight, as well as issues related to weight stigma and patient engagement in the clinical setting. We achieved consensus on 42 clinical recommendations that address these questions. An algorithm describing obesity care is presented, keyed to the various consensus recommendations.
Keywords: childhood obesity in Southeast Asia; consensus on obesity in Southeast Asia; obesity management in Southeast Asia; weight stigma in Southeast Asia.
© 2022 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Conflict of interest statement
KWT has disclosed receiving scientific advisory board fees, honoraria and consulting fees from Novo Nordisk, and an honorarium from DKSH Singapore. RAG has received research funding from AstraZeneca, Medtronic, Boehringer Ingelheim and Novo Nordisk, and sponsorship in the form of travel grants from AstraZeneca, Medtronic, Servier, Boehringer Ingelheim, MSD, Novo Nordisk, Novartis, and Eli Lilly. RAG has also received sponsorships for Continuous Medical Education for healthcare providers from Novo Nordisk, and has been involved in clinical trials with Johnson & Johnson, Boehringer Ingelheim, Bayer and AstraZeneca. RAG is currently involved as an investigator on multicentre clinical trials with Novo Nordisk. TN has disclosed receiving scientific advisory board fees from Novo Nordisk, Sanofi, Astra Zeneca, and Boehringer Ingelheim Viet Nam, and honoraria for acting as a speaker for Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Novartis, MSD, and Merck Serono. NS has disclosed that he has received an honorarium for acting as a speaker for Novo Nordisk. BO has received consulting fees and honoraria from Novo Nordisk not related to this publication.
Figures
References
-
- Shekar M, Popkin B. Obesity: Health and Economic Consequences of an Impending Global Challenge. Human Development Perspectives Series. Washington, DC: World Bank; 2020.
-
- World Health Organization . Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed March 2022.
-
- Lobstein T, Brinsden H, Neveux M. World Obesity Atlas 2022. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_202.... Accessed March 2022.
-
- Lear SA, James PT, Ko GT, et al. Appropriateness of waist circumference and waist‐to‐hip ratio cutoffs for different ethnic groups. Eur J Clin Nutr. 2010;64(1):42‐61. - PubMed
-
- WHO Expert Consultation . Appropriate body‐mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157‐163. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
